Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2017

View Archived Issues

AVROBIO licenses cystinosis program from Genstem Therapeutics

CD36 is a promising drug target for treating T2DM

Board recommends continuing Athenex's phase III Oraxol 001 study

Sirtuin-6 could be modulated to prevent NASH progression

FDA gives orphan drug status to CytoDyn's PRO-140

PCI Biotech's fimaporfin wins orphan drug status in U.S.

Kyowa Hakko Kirin doses first patient in phase II trial of entinostat

Aerie Pharmaceuticals acquires rights to PRINT technology in ophthalmology

Monoclonal antibodies developed to target both dengue and Zika viruses

FDA accepts Methylene Blue MMX NDA

Immatics closes USD 58 million series E financing

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Emory University patents antiviral compounds for hepatitis B, hepatitis C and West Nile viruses

The University of California, Oakland presents novel apoptosis inducers and splicing modulators

STAT3-targeting antibody SBT-100 given U.S. orphan drug designation

GlaxoSmithKline identifies novel integrin alphavbeta6 receptor antagonists

Novel oligopeptides created at Guangzhou Nuowei Biotechnology

AstraZeneca identifies new serine-protein kinase ATM inhibitors

FDA approves cobas Zika test to screen blood donations

Zealand establishes research collaboration with Torrey Pines Institute for Molecular Studies

Acadia Pharmaceuticals starts phase III HARMONY trial of Nuplazid

KemPharm and Genco sign licensing agreement to develop prodrug for pediatric Tourette's with ADHD

Phase III TIVO-3 trial of Fotivda to continue as planned following futility analysis

Role of CD36 in islet dysfunction makes it a target for treating diabetes

AOBiome begins enrollment in phase Ib/IIa of AOB product for SAR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...